Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

By Minji Jo, Tae-Hyoung Kim, D. Seol, James E. Esplen, K. Dorko, Timothy R. Billiar, S. Strom. Nature Medicine, 2000

899 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy (2006, background): “However, some concerns about potential toxic side effects on human hepatocytes or brain tissue have also been raised (Jo et al., 2000; Nitsch et al., 2000).”
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions (2001, methodology): “His using methods similar to those used by Jo et al.(8) and compared it with Apo2L/TRAIL.”
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. (2003, background): “Hepatocytes and keratinocytes are resistant to this optimized ligand version [26,27] but show significant sensitivity to apoptosis induction by non-optimized or antibody-crosslinked variants of the ligand [25].”
Apo2L/TRAIL and its death and decoy receptors (2003, background): “evaluating results: some preparations lacking the Zn have reduced solubility and tend to aggregate, perhaps explaining the reported toxicity of certain Apo2L/TRAIL preparations to human hepatocytes.(24,25) Untagged, trimeric Apo2L/TRAIL containing stoichiometric Zn at doses up to 100 mg/ml did not i”